When nanomedicines meet tropical diseases

• Eder Lilia Romero,
• Katrien Van Bocxlaer and
• Fabio Rocha Formiga

Beilstein J. Nanotechnol. 2024, 15, 830–832, doi:10.3762/bjnano.15.69

• ; Chagas disease; leishmaniasis; nanomedicine; nanotechnology; neglected tropical diseases; schistosomiasis; In May 2021, the World Health Assembly from the World Health Organization (WHO) decided to officially recognize January 30th as the World Neglected Tropical Diseases Day. This initiative was done

• Chagas disease. In addition, emerging diseases such as dengue, chikungunya, and zika infections are also considered NTDs. Historically, NTDs have long been overlooked in the global health agenda, attracting little attention and low funding. Currently, there are few tools available to diagnose and treat

• article collection. Among the articles, an interesting strategy to improve the bioavailability of benzonidazole towards Chagas disease has been presented by Muraca and colleagues, who reported a stable and safe nanostructured lipid formulation with potential effects against Trypanosoma cruzi [2]. In turn

Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• Subodh Chandra Mallick Rd., Jadavpur, Kolkata 700032, West Bengal, India 10.3762/bjnano.15.30 Abstract Chagas disease (CD) is the most important endemic parasitosis in South America and represents a great socioeconomic burden for the chronically ill and their families. The only currently available

• drugs with low molecular weight [1][2]. Different 2-nitroimidazole-based nanomedicines against Chagas disease (CD) to reduce the toxicity and increase the effectiveness of benznidazole (BNZ) treatment have been preclinically screened in the last two decades (see the recently reviewed BNZ-based

• nanomedicines against CD will be critically analyzed. Review Chagas disease, a threat no longer limited to developing countries Chagas disease is a parasitic, systemic, chronic, and often fatal infection caused by the protozoan Trypanosoma cruzi [4]. The World Health Organization classifies CD as the most

Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies

• Giuliana Muraca,
• María Esperanza Ruiz,
• Rocío C. Gambaro,
• Sebastián Scioli-Montoto,
• María Laura Sbaraglini,
• Gisel Padula,
• José Sebastián Cisneros,
• Cecilia Yamil Chain,
• Vera A. Álvarez,
• Cristián Huck-Iriart,
• Guillermo R. Castro,
• María Belén Piñero,
• Matias Ildebrando Marchetto,
• Catalina Alba Soto,
• Germán A. Islan and
• Alan Talevi

Beilstein J. Nanotechnol. 2023, 14, 804–818, doi:10.3762/bjnano.14.66

• Alan Talevi See end of main text. 10.3762/bjnano.14.66 Abstract Chagas disease is a neglected endemic disease prevalent in Latin American countries, affecting around 8 million people. The first-line treatment, benznidazole (BNZ), is effective in the acute stage of the disease but has limited efficacy

• . These results show potential for the development of new nanomedicines against T. cruzi. Keywords: benznidazole; biopharmaceutical study; Chagas disease; nanoparticles; nanostructured lipid carriers; physicochemical characterization; Trypanosoma cruzi; Introduction Chagas disease is a neglected disease

• chronically infected individuals [1][4]. Currently, two drugs have been approved for the treatment of Chagas disease: benznidazole (BNZ) and nifurtimox. The first-line treatment, BNZ, is a nitroimidazole that generates radical intermediates via the reduction of its nitro group, which covalently bind to

A review on nanostructured silver as a basic ingredient in medicine: physicochemical parameters and characterization

• Gabriel M. Misirli,
• Kishore Sridharan and
• Shirley M. P. Abrantes

Beilstein J. Nanotechnol. 2021, 12, 440–461, doi:10.3762/bjnano.12.36

• used in the future against the increase of multidrug-resistant pathogenic strains. In addition, AgNPs can also be used to combat neglected diseases such as dengue, leishmaniasis, malaria, schistosomiasis, and trypanosomiasis (Chagas disease) among other applications [5][19][24]. The unprecedented

• toxicity and improved efficacy [86]. In vivo and in vitro studies have demonstrated the efficacy of AgNPs in treating neglected diseases, such as dengue [87][88], leishmaniasis [89][90][91][92], malaria [93][94][95], schistosomiasis [96][97], and trypanosomiasis (Chagas disease) [98][99]. Mechanism of